BLU-945 |
| Catalog No.GC63910 |
BLU-945는 강력하고 선택성이 높고 가역적이며 경구 활성인 표피 성장 인자 수용체(EGFR) 티로신 키나제 억제제(TKI)입니다. BLU-945는 L858R 및/또는 엑손 19 결실 돌연변이, T790M 돌연변이 및 C797S 돌연변이로 EGFR을 효과적으로 억제할 수 있습니다. BLU-945는 비소세포폐암(NSCLC)을 포함한 폐암 연구에 사용할 수 있다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2660250-10-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
receptor (EGFR). EGFR is a member of the erbB receptor family, which includes transmembrane protein tyrosine kinase receptors. BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. BLU-945 facilitates efficacious dosing and reduces EGFR-mediated on-target toxicities. S BLU-945 has the potential for the research of cancer disease (extracted from patent WO2021133809A1, compound 112)[1].
[1]. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *